Chemours (CC) Cost of Revenue (2014 - 2026)

Chemours has reported Cost of Revenue for 13 years, with the latest figure at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 3.27% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $4.9 billion (up 5.28% YoY), and the FY2025 full-year result was $4.9 billion, up 5.73% from the prior year.
• Cost of Revenue for Q1 2026 stood at $1.2 billion, roughly flat from $1.2 billion in the prior quarter.
• The five-year high for Cost of Revenue was $1.4 billion in Q2 2022, with the low at $1.1 billion in Q1 2024.
• Average Cost of Revenue over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2024.
• Year-over-year, Cost of Revenue gained 12.2% in 2022 and declined 11.85% in 2023.
• Tracing CC's Cost of Revenue over 5 years: stood at $1.1 billion in 2022, then fell by 2.11% to $1.1 billion in 2023, then retreated by 1.71% to $1.1 billion in 2024, then gained by 7.31% to $1.2 billion in 2025, then dropped by 0.43% to $1.2 billion in 2026.
• The last three Cost of Revenue figures came in at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.

Peer Comparison